Heat-inactivated vaccinia virus as a vaccine immune adjuvant
AssigneeMemorial Sloan Kettering Cancer Center
InventorsLiang DENG, Jedd D. WOLCHOK, Taha MERGHOUB, Stewart SHUMAN, Ning YANG
Life of this patent
Estimating the term…
Abstract
The technology of the present disclosure relates to the use of Heat-inactivated modified vaccinia Ankara (MVA) vims (Heat-iMVA) or Heat-inactivated vaccinia vims as a vaccine immune adjuvant. In particular, the present technology relates to the use of Heat-iMVA as a vaccine adjuvant for tumor antigens in cancer vaccines alone or in combination with immune checkpoint blockade (ICB) antibodies for use as a cancer immunotherapeutic.
Claims32
A method for treating a solid tumor in a subject in need thereof, the method comprising administering to the subject an immunogenic composition comprising an antigen and a therapeutically effective amount of an adjuvant comprising an inactivated modified vaccinia Ankara virus and/or an inactivated vaccinia virus.
An immunogenic composition comprising an antigen and an adjuvant comprising an inactivated modified vaccinia Ankara virus and/or an inactivated vaccinia virus.
A kit comprising instructions for use, a container means, and a separate portion of each of:
- (a) an antigen;
- and (b) an adjuvant comprising inactivated modified vaccinia Ankara virus and/or inactivated vaccinia virus.
Dependencies are inferred from the claim text.